• Markets
    • icon
  • Companies
DXB · ASX

Dimerix Limited (ASX:DXB)

AU$0.15

 0.0 (0.0%)
ASX:Live
06/12/2023 04:10:05 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

DXB Overview

DXB Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About DXB

Website

Dimerix Limited

Telephone

61.8.1300.8133

Address

Fitzroy 425 Smith Street Melbourne, Victoria (VIC) 3065

Description

Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. It focuses on the development of Dimerix DMX-200 drug candidate in both renal and respiratory indications and the development of Dimerix DMX-700 pre-clinical asset in Chronic Obstructive Pulmonary Disease. The company was founded on May 13, 1975 and is headquartered in Melbourne, Australia.

DXB Price Chart

Key Stats

Market Cap

AU$61.78M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.05 - 0.23

Trade Value (12mth)

AU$47,897.00

1 week

11.11%

1 month

-11.76%

YTD

5.28%

1 year

-1.51%

All time high

44.7415

Key Fundamentals

EPS 3 yr Growth

61.800%

EBITDA Margin

N/A

Operating Cashflow

-$13m

Free Cash Flow Return

-124.80%

ROIC

-135.30%

Interest Coverage

N/A

Quick Ratio

1.50

Other Data

Shares on Issue (Fully Dilluted)

337m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

DXB Announcements

Latest Announcements

Date Announcements

31 October 23

Notification of cessation of securities - DXB

×

Notification of cessation of securities - DXB

31 May 22

Phase 3 FSGS Kidney Trial First Patient Recruited

×

Phase 3 FSGS Kidney Trial First Patient Recruited

31 January 23

Quarterly Appendix 4C and Activities Report

×

Quarterly Appendix 4C and Activities Report

30 September 20

AGM Presentation

×

AGM Presentation

30 September 08

Annual Report to shareholders

×

Annual Report to shareholders

30 October 23

Quarterly Appendix 4C and Activities Report

×

Quarterly Appendix 4C and Activities Report

30 October 19

Ausbiotech Conference Presentation

×

Ausbiotech Conference Presentation

30 October 18

AGM Presentation and CEO Address

×

AGM Presentation and CEO Address

30 November 07

Results of Annual General Meeting

×

Results of Annual General Meeting

30 August 23

Preliminary Final Report

×

Preliminary Final Report

30 August 23

Annual Report

×

Annual Report

30 August 23

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

30 August 18

Annual Report to shareholders

×

Annual Report to shareholders

30 August 17

Annual Report to shareholders

×

Annual Report to shareholders

29 September 10

Annual Report (SBN-AU)

×

Annual Report (SBN-AU)

29 October 19

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

29 October 07

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

29 November 22

Chair address and CEO presentation to AGM

×

Chair address and CEO presentation to AGM

29 November 22

Results of Meeting

×

Results of Meeting

29 November 22

Constitution

×

Constitution

29 March 22

Investor Presentation

×

Investor Presentation

29 March 22

Dimerix Receives A$3.7M R&D Tax Incentive Rebate

×

Dimerix Receives A$3.7M R&D Tax Incentive Rebate

29 March 21

Investor Presentation

×

Investor Presentation

29 June 23

Notification regarding unquoted securities - DXB

×

Notification regarding unquoted securities - DXB

29 June 23

Notification regarding unquoted securities - DXB

×

Notification regarding unquoted securities - DXB

29 June 23

Application for quotation of securities - DXB

×

Application for quotation of securities - DXB

29 June 23

Application for quotation of securities - DXB

×

Application for quotation of securities - DXB

29 June 23

Application for quotation of securities - DXB

×

Application for quotation of securities - DXB

DXB Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.04 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.9 -10.6 -19.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.05 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -43.9 1.6 -10.4 Lock Lock Lock
     Yield % Lock Lock Lock Lock -16.8 -38.1 -63.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.04 0.02 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.04 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -81.1 506.0 -65.8 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 198 294 326 Lock Lock Lock
Basic m Lock Lock Lock Lock 198 294 326 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 11 17 23 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -229.7 -13.3 -10.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -17 -23 Lock Lock Lock
     Growth % Lock Lock Lock Lock -57.6 -55.3 -34.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -11 -17 -23 Lock Lock Lock
     Growth % Lock Lock Lock Lock -58.0 -55.2 -34.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -10 -17 -23 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -4 -6 -9 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -6 -10 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.8 -64.6 -31.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -6 -13 -13 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 4 18 11 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -6 -13 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -37.1 -107.8 5.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 5 10 8 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 9 16 18 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 0 -10 -2 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 8 2 12 Lock Lock Lock
Equity $m Lock Lock Lock Lock 1 14 6 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 1 14 6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -81.1 883.6 -58.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -67.6 -63.6 -77.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -433.9 -72.7 -231.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -142.6 -161.4 -172.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -138.1 -131.9 -135.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -140.1 -168.9 -124.8 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A -14,573.0 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.0 0.6 0.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -14.1 -66.3 -34.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.2 8.1 1.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.2 8.1 1.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 55.7 58.4 45.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -81.3 -664.0 -108.3 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -67.6 -63.6 -77.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 6.4 1.1 3.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -433.9 -72.7 -231.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -433.9 -72.7 -231.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 15,020.6 13,129.5 20,391.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -15,020.6 -13,129.5 -20,391.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

DXB Shortsell

Frequently Asked Questions

The current share price of Dimerix Limited (DXB:ASX) is AU$0.15.
The 52-week high share price for Dimerix Limited (DXB:ASX) is AU$0.23.
The 52-week low share price for Dimerix Limited (DXB:ASX)? is AU$0.05.
Dimerix Limited (DXB:ASX) does not pay a dividend.
Dimerix Limited (DXB:ASX) does not pay a dividend.
Dimerix Limited (DXB:ASX) does not offer franking credits.
Dimerix Limited (DXB:ASX) is classified in the Healthcare.
The current P/E ratio for Dimerix Limited (DXB:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.